Targeting immunometabolism in host-directed therapies to fungal disease
Author(s) -
Samuel M. Gonçalves,
Anaísa V. Ferreira,
Cristina Cunha,
Agostinho Carvalho
Publication year - 2021
Publication title -
clinical and experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1093/cei/uxab014
Subject(s) - immune system , biology , effector , immunology , immunity , antifungal , reprogramming , disease , mechanism (biology) , medicine , microbiology and biotechnology , cell , philosophy , genetics , epistemology , pathology
Summary Fungal infections affect over a billion people and are responsible for more than 1.5 million deaths each year. Despite progress in diagnostic and therapeutic approaches, the management of severe fungal infections remains a challenge. Recently, the reprogramming of cellular metabolism has emerged as a central mechanism through which the effector functions of immune cells are supported to promote antifungal activity. An improved understanding of the immunometabolic signatures that orchestrate antifungal immunity, together with the dissection of the mechanisms that underlie heterogeneity in individual immune responses, may therefore unveil new targets amenable to adjunctive host-directed therapies. In this review, we highlight recent advances in the metabolic regulation of host–fungus interactions and antifungal immune responses, and outline targetable pathways and mechanisms with promising therapeutic potential.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom